Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Japanese transplant recipient study of maribavir for CMV infection
2022-002374-82Phase 3
- Sponsor
- Takeda
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of maribavir in cytomegalovirus disease (CMV), sponsored by Takeda. Primary endpoint: Percentage of participants with CMV viremia clearance.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2022-002374-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002374-82.